Journal article

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

Roger L Milne, Ana Osorio, Teresa Ramon y Cajal, Montserrat Baiget, Adriana Lasa, Eduardo Diaz-Rubio, Miguel de la Hoya, Trinidad Caldes, Alex Teule, Conxi Lazaro, Ignacio Blanco, Judith Balmana, Gessami Sanchez-Olle, Ana Vega, Ana Blanco, Isabel Chirivella, Eva Esteban Cardenosa, Mercedes Duran, Eladio Velasco, Eduardo Martinez de Duenas Show all

Breast Cancer Research and Treatment | SPRINGER | Published : 2010


Awarded by Fondo de Investigacion Sanitario

Awarded by RTICC

Awarded by Fundacion de Investigacion Medica Mutua Madrilena

Awarded by Ministerio de Sanidad y Consumo

Awarded by Xunta de Galicia

Awarded by Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III

Funding Acknowledgements

We thank the patients and families without whose generous participation this study would not have been possible. We also thank Alicia Barroso and Fernando Fernandez who conducted the genetic testing at the Centro Nacional de Investigaciones Oncologicas; Guillermo Pita for information technology support; Marina Pollan and Fernando Artalejo from the Universidad Autonoma de Madrid; M. Carmen Alonso, Consol Lopez and David Fisas from the Hospital de la Santa Creu i Sant Pau; Daniel Fortuny, Neus Gadea, and Orland Diez from Hospital Vall d'Hebron; Vicenta Garces from the Hospital Clinico Universitario de Valencia, Pascual Bolufer from the Laboratorio de Biologia Molecular, Hospital La Fe de Valencia; Dolores Salas and Dolores Cuevas from the Grupo de Cancer Hereditario, Comunidad Valenciana. This work was partly supported by a grant from the Fondo de Investigacion Sanitario [PI081120]. TC, MdH and ED-R were supported by the RTICC (RD06/0020/0021), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation and a grant from the Fundacion de Investigacion Medica Mutua Madrilena (FMMA/06). The work at the Instituto Catalan de Oncologia was supported by grants ISCIII-RETIC RD06/0020/1051 and 2005SGR00018. The Fundacion Publica Galega de Medicina Xenomica -SERGAS component of this work was partially supported by grants from the Ministerio de Sanidad y Consumo (PI052275) and the Xunta de Galicia (PGIDIT06BTF910101PR) to AV. AB has a fellowship from the Instituto de Salud Carlos III. The work at the Instituto de Biologia y Genetica Molecular was partly supported by the Hereditary Cancer Prevention Programme of the Regional Government of Castilla y Leon, and grant PI06/1102 (Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III). The work at the Hospital de Cruces was funded by the grant BIO07/CA/006.